He is Professor Emeritus at The Scripps Research Institute and was co-founder of Neurome, Inc. where he served as Chairman, Chief Executive Officer and Chief Scientific Officer. From 1989 until March 2005, he served as Chairman of the Department of Neuropharmacology at The Scripps Research Institute. Prior to that, he was Head, Division of Preclinical Neuroscience and Neuropharmacology in the Department of Medicine at the Scripps Clinic and Research Foundation. In addition to serving on the scientific advisory boards of several major pharmaceutical organizations, Dr. Bloom is also a founder of Alkermes, Inc., a $6.2 billion company whose successfully commercialized products include treatments for schizophrenia and bipolar disorder, and serves on Alkermes’ Board of Directors.
A member of the National Academy of Sciences since 1977, he is the recipient of numerous prizes for his contributions to science, including the Janssen Award in the Basic Sciences and the Pasarow Award in Neuropsychiatry. He is a member of the Royal Swedish Academy of Sciences, the National Academy of Medicine, and its Institute of Medicine, as well as the American Academy of Arts and Sciences and the American Philosophical Society. Dr. Bloom’s more than 600 publications include the seminal work: The Biochemical Basis of Neuropharmacology. He holds an A.B. (Phi Beta Kappa) from Southern Methodist University and an M.D. (Alpha Omega Alpha) from Washington University School of Medicine in St. Louis.